A mutation in QRDR in the ParC subunit of topoisomerase IV was responsiblefor fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae
Citation
H. Choi et al., A mutation in QRDR in the ParC subunit of topoisomerase IV was responsiblefor fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae, YONSEI MED, 39(6), 1998, pp. 541-545
Categorie Soggetti
General & Internal Medicine
Journal title
YONSEI MEDICAL JOURNAL
SICI code
0513-5796(199812)39:6<541:AMIQIT>2.0.ZU;2-5
Abstract
Forty-one strains of Streptococcus pneumoniae were isolated at Seoul Nation
al University Children's Hospital from 1991 to 1997. Isolates were divided
into six groups based on MICs of three quinolones, ciprofloxacin, ofloxacin
and norfloxacin. Sequencing showed that the isolates which were intermedia
tely resistant to three quinolones or resistant to at least one kind of qui
nolone had one missense mutation, Lys137 --> Asn (AAG --> AAT) substitution
in the ParC subunit of topoisomerase IV without additional mutation in QRD
R of the GyrA subunit of DNA gyrase. In conclusion, the ParC subunit of DNA
topoisomerase IV is the primary target site for fluoroquinolone in S. pneu
moniae and Lys137 --> Asn substitution renders the quinolone resistance in
S. pneumoniae..